In Section A, contributors will obtain unique doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. Supplemental participants might be enrolled in the recognized monotherapy dosign routine. In Section B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "increase-on" therapy. In Phase C, participants https://kingf444sdn6.wikiconverse.com/user